183 filings
8-K
SABS
SAB Biotherapeutics Inc
15 Apr 24
Regulation FD Disclosure
5:15pm
8-K
SABS
SAB Biotherapeutics Inc
29 Mar 24
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
9:35am
8-K
SABS
SAB Biotherapeutics Inc
8 Mar 24
Entry into a Material Definitive Agreement
4:30pm
S-8
SABS
SAB Biotherapeutics Inc
23 Feb 24
Registration of securities for employees
4:18pm
8-K
SABS
SAB Biotherapeutics Inc
2 Feb 24
SAB Biotherapeutics Announces Executive Leadership Change
7:53am
8-K
22msdfhout mnvuom
26 Jan 24
Entry into a Material Definitive Agreement
4:15pm
424B5
chjf2
26 Jan 24
Prospectus supplement for primary offering
4:00pm
8-K
f27q1hpjis48p ya4
25 Jan 24
Other Events
5:00pm
8-K
m718gac99bp
19 Jan 24
Regulation FD Disclosure
4:21pm
8-K
7benx svmz7b93
3 Jan 24
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
9:00am
8-K
j0pw 8wdozcdj8y
29 Nov 23
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying
7:40am
EFFECT
jafqekh668g vwo
29 Nov 23
Notice of effectiveness
12:15am
CORRESP
woec5ho ls9
24 Nov 23
Correspondence with SEC
12:00am
8-K
yfa540sl5kz4zena9
22 Nov 23
Amendments to Articles of Incorporation or Bylaws
4:45pm
8-K
9799y q74laqo
20 Nov 23
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
5:00pm
S-3/A
p2gvybih rk
20 Nov 23
Shelf registration (amended)
4:45pm
DEFA14A
icp7xgjte ajhcgwajsq
14 Nov 23
Additional proxy soliciting materials
4:31pm
8-K/A
ua8thrjhyc928c8ph8tj
14 Nov 23
Unregistered Sales of Equity Securities
4:31pm